SenzaGen hosts open webinars on Respiratory Sensitization on 4 and 5 December

In vitro testing for Respiratory Sensitizers using a genomic biomarker signature and the GARD™ technology platform The presentations on 4 and 5 December 2018, will give insight into the latest in vitro technology for identifying respiratory sensitizers using human dendritic-like cell lines and genomics.  A thorough explanation of the GARD™ platform will be covered as well […]

In vitro testing for Respiratory Sensitizers using a genomic biomarker signature and the GARDtechnology platform

The presentations on 4 and 5 December 2018, will give insight into the latest in vitro technology for identifying respiratory sensitizers using human dendritic-like cell lines and genomics.  A thorough explanation of the GARD platform will be covered as well as its versatility and reliability for safety assessment applicable to all industries. Sensitization testing with GARD is based on functional genomics.

The presentation will cover:

  • Development of the genomic-based GARD test platform for skin sensitization hazard, potency classification, and now also respiratory sensitization.
  • Dendritic cells – why they are also relevant for respiratory sensitization.
  • Gene mapping – what genes are in the assay, and how are they relevant for sensitization.
  • How GARD can discriminate between skin and respiratory sensitization and why this is relevant.
  • Update on the development of the SenzaGen R&D pipeline including GARD for materials – testing medical devices, GARD for proteins – classification of protein sensitizers, GARD for mixtures – assessment of complex formulations and Unknown or Variable Composition UVCBs.

Next generation in vitro skin and respiratory sensitization testing using genomics with GARD

The GARD™ platform is a versatile in vitro testing strategy which currently consist of three assays targeting two toxicological endpoints: skin sensitization (GARDskin & GARDpotency) and respiratory sensitization (GARDair). These assays make use of unique genomic biomarker signatures comprising genes involved in pathways known to be immunologically relevant to the sensitization process. Supported by modern technologies for pattern recognition, the large informational content provided by this approach enable for mechanism-of-action based decisions, which becomes evident in a consistently high predictive accuracy

Don’t miss the opportunity to learn more from our researchers.

Register by clicking on any of the links below.

 

European Registration
Tue 4 Dec 2018, 15:00 CET

Americas Registration
Wed 5 Dec 2018, 13:00 EST